Bracanalysis Cdx News Today

SALT LAKE CITY, May 23, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, and its collaborators will share data from seven

Molecular Residual Disease study and multiple RiskScore studies among seven new datasets to be shared by Myriad and Collaborators SALT LAKE CITY, May 23, 2024 -- Myriad Genetics, Inc., , a leader...

Company Raises 2024 Revenue Guidance and Delivers Positive Adjusted EPS in Q4

On December 31, 2023, Glenview Capital Management, led by Larry Robbins (Trades, Portfolio), made a significant addition to its investment portfolio by acquiring 1,500,000 shares of Myriad Genetics Inc (NASDAQ:MYGN). The trade had a 0.65% impact on the portfolio, bringing the position to 2.29% of the portfolio and 5.97% of the company's shares.

Unpacking the Risks and Rewards of Investing in Myriad Genetics (MYGN)

SALT LAKE CITY, Sept. 28, 2023 /PRNewswire/ -- A new national survey from Myriad Genetics Inc., , a leader in genetic testing and precision medicine, revealed that breast density and family health...

Unmasking the Risks and Rewards of Investing in Myriad Genetics (MYGN)

Unraveling the complexities of Myriad Genetics' financial health and potential risks for investors

Myriad Genetics, Inc. (NASDAQ:MYGN) Q2 2023 Earnings Call Transcript August 3, 2023 Operator: Greetings, and welcome to the Myriad Genetics Second Quarter 2023 Financial Earnings Call [Operator Instructions]. As a reminder, this conference is being recorded Thursday, August 3, 2023. I’d now like to turn the call over to Matt Scalo, Senior Vice President, Investor […]

Global Next-Generation Breast Cancer Diagnostic and Screening Market to Reach $9.88 Billion by 2032 – BIS Research Market Intelligence Report